Childhood Cancer Linked with Abnormal Antibodies - Inside Precision Medicine
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.

Credit: FatCamera / Getty Images Children who develop cancer produce an unusually high number of antibodies that attack DNA repair machinery, new research suggests. The findings, published in Frontiers in Immunology, could help lead to early screening that prevents cancer from developing later on, during adolescence.
The pathogenic, penetrating autoantibodies, which can cross over into cells, predominantly targeted six proteins involved in DNA repair. They may represent a previously unrecognized mechanism through which people are predisposed to cancer at a young age.
This article is an excerpt. To read the full content, visit the original source. Inside Precision Medicine
Related articles

Unsuspected discovery of abnormal antibodies could explain pediatric cancer - Frontiers
Researchers have found the first evidence for a previously unsuspected cause of pediatric cancer. They showed that children with such cancers were more likely than their healthy peers to produce ‘auto-antibodies’ targeting six proteins necessary for normal DNA repair. Likewise, they showed that young adults with cancer had greater amounts of these circulating antibodies already years before diagnosis. Tests confirmed that such antibodies can enter the cell during division, where they seem to locate to the TIGER domain implicated in translation and bind their antigens there. The latter result immediately suggests a likely mechanism for the etiology of cancer through the immobilization of DNA repair proteins. A team of scientists in Norway has found evidence for a new, previously unknown mechanism for the development of cancer in children: they seem to produce an unusual amount of aberrant antibodies against the building blocks that make up the DNA repair machinery, a diverse set of hundreds of proteins which identify and correct damage or errors in the genome.

Breast milk antibodies show promise against multiple respiratory viruses - News-Medical
Yona Tugg and colleagues show that a polyclonal secretory immunoglobulin A preparation, purified from breast milk pooled from multiple donors, neutralized respiratory syncytial virus (RSV), human adenovirus type 5, and H1N1 and H3N2 influenza A viruses in laboratory assays. In mouse models of H1N1 influenza infection, two intranasal doses of LCTG-001, given two hours before and 24 hours after infection, reduced illness and lung damage in both immunocompetent and antibody-deficient mice. In immunocompetent mice, lung viral loads were lower early in infection but comparable to controls later, despite less lung damage and better lung barrier integrity.
Patient-centered financial navigation assistance helps reduce financial toxicity among cancer patients - Medical Xpress
Among cancer patients, the high financial cost of cancer care is a prevalent problem. This financial burden is also associated with potentially harmful behavioral strategies that patients might use to cope with costs, such as delaying or forgoing treatment and skipping medications. Collectively, researchers refer to this impact as financial toxicity.

Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress
Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.
Wearing headphones during surgery may reduce nausea and vomiting afterward - Medical Xpress
Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.
0 comments
No comments yet. Be the first to share your thoughts!